Drug General Information (ID: DDICET62W4)
Drug Name			Olanzapine		Drug Info		Inotuzumab ozogamicin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antipsychotic Agents				Antineoplastics

Mechanism of Olanzapine-Inotuzumab ozogamicin Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Olanzapine				Inotuzumab ozogamicin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Olanzapine and Inotuzumab ozogamicin

Recommended Action
Management		Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Zyprexa (olanzapine). Lilly, Eli and Company, Indianapolis, IN.